Loss to Follow up in Patients with Proliferative Diabetic Retinopathy Treated with Anti-VEGF Therapy and/or Panretinal Photocoagulation in the United States
- 23 April 2024
- journal article
- research article
- Published by Elsevier in Ophthalmology Retina
- Vol. 8 (10) , 953-961
Abstract
No abstract availableKeywords
Funding Information
- American Academy of Ophthalmology
This publication has 19 references indexed in Scilit:
- Disparities in Vision Health and Eye CareOphthalmology, 2022
- Intravitreal anti-vascular endothelial growth factor versus panretinal LASER photocoagulation for proliferative diabetic retinopathy: a systematic review and meta-analysisCanadian Journal of Ophthalmology, 2021
- Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045Ophthalmology, 2021
- Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic RetinopathyJAMA Ophthalmology, 2021
- Predictors of Lost to Follow-Up in Patients Being Treated for Proliferative Diabetic RetinopathyAmerican Journal of Ophthalmology, 2020
- Loss to Follow-Up Among Patients With Proliferative Diabetic Retinopathy in Clinical PracticeAmerican Journal of Ophthalmology, 2020
- Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti–Vascular Endothelial Growth FactorOphthalmology, 2019
- Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF InjectionsOphthalmology, 2018
- The 2016 American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) DatabaseOphthalmology, 2018
- Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic RetinopathyJAMA, 2015